Valion Bio, Inc. Common Stock VBIO

$1.04 -6.98% at last close

Recent SEC Filings

FormDescriptionFiledDocument
8-K FORM 8-K 2026-10-22 View →
S-3 REGISTRATION STATEMENT 2026-10-16 View →
DEF 14A DEFINITIVE PROXY STATEMENT 2026-10-16 View →
8-K CURRENT REPORT 2026-10-15 View →
8-K CURRENT REPORT 2026-10-14 View →
8-K CURRENT REPORT 2026-10-08 View →
S-3 REGISTRATION STATEMENT 2026-10-08 View →
8-K FORM 8-K 2026-10-06 View →
8-K CURRENT REPORT 2026-10-01 View →
4 Insider transaction 2026-09-24 View →
4 Insider transaction 2026-09-24 View →
8-K FORM 8-K 2026-09-23 View →
8-K FORM 8-K 2026-09-01 View →
8-K CURRENT REPORT 2026-08-27 View →
8-K CURRENT REPORT 2026-08-17 View →
10-Q FORM 10-Q 2026-08-14 View →
8-K CURRENT REPORT 2026-08-06 View →
DEF 14A DEFINITIVE PROXY STATEMENT 2026-07-17 View →
S-1 DRAFT REGISTRATION STATEMENT 2026-07-17 View →
8-K CURRENT REPORT 2026-07-14 View →
4 Insider transaction 2026-06-18 View →
8-K CURRENT REPORT 2026-06-18 View →
8-K CURRENT REPORT 2026-06-03 View →
4 Insider transaction 2026-05-20 View →
10-Q FORM 10-Q 2026-05-14 View →
8-K FORM 8-K 2026-05-14 View →
4 Insider transaction 2026-05-04 View →
8-K FORM 8-K 2026-05-04 View →
DEF 14A DEFINITIVE PROXY STATEMENT 2026-04-30 View →
8-K CURRENT REPORT 2026-04-23 View →
4 Insider transaction 2026-04-20 View →
S-1 FORM S-1 2026-04-13 View →
4 Insider transaction 2026-04-02 View →
10-K FORM 10-K 2026-03-30 View →
8-K FORM 8-K 2026-03-25 View →
8-K FORM 8-K 2026-03-20 View →
4 Insider transaction 2026-03-19 View →
8-K CURRENT REPORT 2026-03-13 View →
8-K FORM 8-K 2026-03-11 View →
8-K CURRENT REPORT 2026-03-04 View →

Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.

Key Stats

Last Close
$1.04
Market Cap
$994,100
52-Week Range
$1.04 – $32.50
Average Volume
2.82 million shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.